A. Balogh

Neither Boosted Elvitegravir nor Darunavir with Emtricitabine/Tenofovir Disoproxil Fumarate Increase Insulin Resistance in Healthy Volunteers: Results from the STRIBILD-IR Study

R. Schmid, E. Wolf, C. Spinner, 2016, Antiviral therapy.

Highly specific reasons for nonadherence to antiretroviral therapy: results from the German adherence study

I. Krznaric, E. Wolf, C. Spinner, 2017, Patient preference and adherence.

HIV and SARS-CoV-2 co-infection: cross-sectional findings from a German ‘hotspot’

E. Wolf, H. Jaeger, F. Tiller, 2021, Infection.

Dolutegravir Monotherapy as Treatment De-Escalation in HIV-Infected Adults with Virological Control: DoluMono Cohort Results

E. Wolf, C. Spinner, H. Jaeger, 2016, Antiviral therapy.

Functional Hypogonadism and Testosterone Deficiency in Aging Males With and Without HIV-infection.

E. Wolf, M. Obermeier, H. Jaeger, 2021, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

Virologic outcomes of switching to boosted darunavir plus dolutegravir with respect to history of drug resistance

H. Stellbrink, C. Boesecke, T. Kümmerle, 2021, AIDS Research and Therapy.

Switching to a NRTI-free 2 drug regimen (2DR) –a sub-analysis of the 48 weeks DUALIS study on metabolic and renal changes

H. Jessen, H. Stellbrink, C. Boesecke, 2022, HIV Research & Clinical Practice.